North China Pharmaceutical Co Ltd (600812) — Cash Flow-to-Debt Ratio
North China Pharmaceutical Co Ltd (600812) has a Cash Flow-to-Debt Ratio of 0.01x as of September 2025, meaning its operating cash flow of CN¥170.24 Million could theoretically repay 0% of its total liabilities (CN¥14.86 Billion) in one year. See North China Pharmaceutical Co Ltd free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
North China Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio (1998–2025)
Historical debt coverage capacity for North China Pharmaceutical Co Ltd across 28 annual periods. Also explore North China Pharmaceutical Co Ltd annual equity growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for North China Pharmaceutical Co Ltd (1998–2025)
Year-by-year debt coverage analysis for North China Pharmaceutical Co Ltd. For market capitalisation and broader financial context, see North China Pharmaceutical Co Ltd (600812) total market value.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.08x | CN¥1.18 Billion | CN¥14.51 Billion | ▼ -2.4% |
| 2024 | 0.08x | CN¥1.23 Billion | CN¥14.80 Billion | ▲ +19.1% |
| 2023 | 0.07x | CN¥1.02 Billion | CN¥14.69 Billion | ▲ +4.1% |
| 2022 | 0.07x | CN¥1.00 Billion | CN¥14.99 Billion | ▲ +14.3% |
| 2021 | 0.06x | CN¥1.05 Billion | CN¥17.91 Billion | ▲ +31.6% |
| 2020 | 0.04x | CN¥752.15 Million | CN¥16.88 Billion | ▼ -21.5% |
| 2019 | 0.06x | CN¥732.97 Million | CN¥12.92 Billion | ▼ -9.1% |
| 2018 | 0.06x | CN¥774.33 Million | CN¥12.40 Billion | ▲ +158.0% |
| 2017 | 0.02x | CN¥287.25 Million | CN¥11.87 Billion | ▲ +160.6% |
| 2016 | -0.04x | CN¥-446.53 Million | CN¥11.18 Billion | ▼ -449.6% |
| 2015 | 0.01x | CN¥122.50 Million | CN¥10.73 Billion | ▲ +30.1% |
| 2014 | 0.01x | CN¥90.56 Million | CN¥10.32 Billion | ▲ +167.7% |
| 2013 | -0.01x | CN¥-135.03 Million | CN¥10.41 Billion | ▼ -89.9% |
| 2012 | -0.01x | CN¥-63.92 Million | CN¥9.36 Billion | ▼ -129.9% |
| 2011 | 0.02x | CN¥227.60 Million | CN¥9.95 Billion | ▲ +130.3% |
| 2010 | -0.08x | CN¥-598.35 Million | CN¥7.94 Billion | ▼ -147.8% |
| 2009 | 0.16x | CN¥1.01 Billion | CN¥6.41 Billion | ▼ -22.0% |
| 2008 | 0.20x | CN¥1.09 Billion | CN¥5.37 Billion | ▲ +58.8% |
| 2007 | 0.13x | CN¥664.37 Million | CN¥5.22 Billion | ▲ +19.8% |
| 2006 | 0.11x | CN¥597.12 Million | CN¥5.61 Billion | ▲ +163.2% |
| 2005 | 0.04x | CN¥224.17 Million | CN¥5.55 Billion | ▼ -23.3% |
| 2004 | 0.05x | CN¥310.39 Million | CN¥5.89 Billion | ▼ -59.1% |
| 2003 | 0.13x | CN¥580.32 Million | CN¥4.51 Billion | ▼ -25.2% |
| 2002 | 0.17x | CN¥738.50 Million | CN¥4.29 Billion | ▲ +117.1% |
| 2001 | 0.08x | CN¥367.28 Million | CN¥4.63 Billion | ▲ +94.0% |
| 2000 | 0.04x | CN¥133.49 Million | CN¥3.27 Billion | ▲ +131.7% |
| 1999 | -0.13x | CN¥-373.62 Million | CN¥2.90 Billion | ▲ +20.8% |
| 1998 | -0.16x | CN¥-326.74 Million | CN¥2.01 Billion | — |